Radiopharm (ASX:RAD) to present on Ga68-Integrin (RAD301) at EANM Congress

Highlights

• Radiopharm’s RAD301 asset targeting pancreatic cancer has been selected for an oral presentation at the 35th Annual Congress of the EANM.
• The conference is strongly aided by numerous industrial exhibitors with global footprint.
• The company entered into an exclusive licence agreement with TRIMT in August last year to develop radiopharmaceuticals, including Ga68-Integrin (RAD301).

Radiopharm Theranostics (ASX:RAD) shares were trading higher in the early hours of 27 September 2022. The uptick of over 3% in the share price was driven by the company’s update on an important recognition of its radiopharmaceuticals, Ga68- Integrin (RAD301).

Radiopharm, along with TRIMT GmbH, has announced that the RAD301 asset targeting pancreatic cancer has been selected for an oral presentation at the 35th Annual Congress of the European Association of Nuclear Medicine (EANM). The asset will be presented during one of the top-rated oral presentation sessions of the Scientific Program of EANM.   

Held once a year, the EANM is a major meeting of physicians and physicists from the nuclear medicine space along with radiopharmacists and radiochemists. The meeting is also attended by other scientific and healthcare staff from Europe and around the globe. Several industrial exhibitors with a global footprint also strongly support the meeting.

The presentation entitled “PET/CT and PET/MR imaging with 68Ga-TVH in patients with pancreatic cancer - First clinical experience” will be made by Dr. Jana Rehm of the Nuclear Medicine Department from the University Hospital Carl Gustav Carus Dresden.

In Aug 2021, Radiopharm entered into an exclusive licence agreement with Targeted Radiopharmaceuticals In Molecular Theranostics (TRIMT) to develop radiopharmaceuticals including Ga68-Integrin (RAD301).

Recognition by EANM committee

Additionally, the clinical evaluation of Ga68-Integrin in PDAC by the team of Prof. Dr Jörg Kotzerke has been picked for Congress Highlights.

Lecture (OP-546) - Tuesday, 18 October 2022 at 8:45 a.m. in Hall 112 within session 1202 - TOP Trials Session 3: New Radiopharmaceutical Trials.

Dr Jakub Simecek, CEO and Co-Founder of TRIMT, said, “We’re thrilled to see this independent endorsement highlighting the significance of our Trivehexin technology at a major radiopharmaceutical meeting, and we look forward to reporting continued progress of the program”.

RAD shares were trading at AU$0.175 early morning on 28 September 2022. The company has a market cap of AU$44.70 million.